Written by The Banking Post
Beacon Pharmaceuticals reported its highest-ever quarterly profit of Tk 522 million for the first quarter of FY26, up 45% year-on-year, driven by higher sales and an expanded distribution network.
The company’s sales revenue rose 46% to Tk 4.09 billion in July–September, supported by strong demand in its oncology and antibiotics segments. “Sales of the oncology and antibiotics segment increased significantly, leading to higher revenue and profit,” said a company official. Beacon Pharma dominates the local oncology market with a 75% market share.
Operating profit also jumped 27% year-on-year to Tk 974 million, while other income, including earnings from bank deposits, added further support to net profit.
Following the earnings announcement, Beacon Pharma’s stock edged up 0.55% to Tk 109.8 per share, even as the broader market remained in the red.
The company’s annual profit for FY25 surged 81% year-on-year to Tk 947 million, on the back of 17% sales growth to Tk 12.54 billion and higher investment income. The board also declared a 21% cash dividend, the highest since its market listing.
Industry insiders say Bangladesh’s growing population and rising healthcare awareness are boosting demand for medicines, particularly for chronic diseases. The Covid-19 pandemic has further highlighted the importance of healthcare preparedness, positively impacting the pharmaceutical sector.
